Clinical trials: Elderly Population
Atrial Fibrillation
Study of DU-176b Aged 80 Years or Older
The purpose of this study is to evaluate the efficacy and safety of edoxaban in patients with non-valvular NVAF aged 80 years or older who are ineligible for available oral anticoagulation therapy.
- Trial name
- NCT02801669
- Testing
- Du-176b
- Where
- 164 sites in Japan
- Volunteers
- 984 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Attention Deficit Hyperactivity Disorder
Phase 3 Randomized Double-Blind Placebo-Controlled Study of NRP104 in Children Aged 6-12 With ADHD
This study is designed to assess efficacy and safety of NRP-104 administered as a daily dose of 30mg, 50mg or 70mg compared to placebo in the treatment of children aged 6-12 years with ADHD.
- Trial name
- NCT00556296
- Testing
- NRP104
- Volunteers
- 297 people
- Sponsor
- New River Pharmaceuticals
Endometriosis
A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain
The purpose of this global Phase 2 study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe…
- Trial name
- ELENA (NCT05560646)
- Testing
- OG-6219
- Where
- 86 sites in United States, Belgium and 9 more
- Volunteers
- 354 people
- Sponsor
- Organon and Co
SARS CoV-2 Infection, Elderly
Effect of the Consumption of a Lactobacillus Strain on the Incidence of Covid-19 in the Elderly
The objective of this trial is to evaluate the effect of the consumption of a probiotic strain on the incidence and severity of COVID-19 in elderly population living in a nursing home.
- Trial name
- NCT04756466
- Testing
- Lactobacillus
- Where
- 3 sites in Spain
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Biosearch S.A.
Respiratory Syncytial Virus Infection, Metapneumovirus Infection
Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older
The purpose of this phase 1 study is to evaluate whether the vaccine is safe and can help the body to develop germ fighting agents called "antibodies" (immunogenicity) against the respiratory syncytial virus (RSV), human…
- Conditions
- Respiratory Syncytial Virus Infection, Metapneumovirus Infection, Parainfluenzae Virus Infection
- Trial name
- NCT06604767
- Testing
- parainfluenza virus type 3 vaccine (PIV3), RSV/hMPV/PIV3 vaccine, RSV/hMPV vaccine
- Where
- 8 sites in Australia
- Volunteers
- 390 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Tonsillitis
Efficacy Study of Pristinamycin Versus Amoxicillin to Treat Tonsillitis Induced by Streptococcus in Children
The primary objective of this study is to demonstrate the non-inferiority, at the assessment visit (V3 (D10/D14)), in terms of bacteriological efficacy of pristinamycin (PRI) administered for 4 days versus amoxicillin (AMX)…
- Trial name
- PRI-angine (NCT00393744)
- Testing
- pristinamycin, amoxicillin
- Where
- France
- Volunteers
- 395 people
- Sponsor
- Sanofi
Pneumococcal Infectious Disease
A Clinical Trial to Observe the Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Target Population
An open clinical trial of a 23-valent pneumococcal polysaccharide vaccine (PPV23) developed by Sinovac Life Science Co., Ltd was conducted to evaluate the safety of Sinovac PPV23 in target population of individuals aged 2 years…
- Trial name
- NCT07071701
- Testing
- 23-valent pneumococcal polysaccharide vaccine, Influenza vaccine
- Where
- China
- Volunteers
- 19,267 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Hypertension
A Clinical Study to Assess Efficacy and Safety of Aliskiren in the Elderly With High Blood Pressure
After a wash-out (1 to 2 weeks), and 2 to 4 week single-blind placebo run-in period, eligible patients will be randomized to receive lisinopril 10 mg, aliskiren 75 mg, 150 mg or 300 mg for a period of 8 weeks
- Trial name
- NCT00219167
- Testing
- aliskiren
- Where
- Switzerland
- Volunteers
- 355 people
- Sponsor
- Novartis
Infections, Streptococcal, Streptococcal Infections
Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine
The purpose of the present study is to assess and compare in healthy non-pregnant women 18 to 40 years of age the safety and immunogenicity of a liquid formulation of Group B Streptococcus (GBS) Trivalent Vaccine (not requiring…
- Trial name
- NCT02270944
- Testing
- GBS Vaccine
- Where
- 9 sites in United States, Belgium and 1 more
- Volunteers
- 1,053 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Varicella
Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old
This is a randomized, blind, controlled clinical trial of live attenuated varicella vaccines manufactured by Shanghai Institute of Biological Products Co.,Ltd.
- Trial name
- NCT05158777
- Testing
- Live attenuated varicella vaccines manufactured by Shanghai Institute of Biological Products Co.,Ltd., Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd
- Where
- China
- Volunteers
- 2,480 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Hypertension, Pulmonary
A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension
The purpose of this study is to evaluate whether the addition of selexipag to standard of care treatment delays disease progression in children with Pulmonary Arterial Hypertension (PAH) in comparison to placebo.
- Trial name
- SALTO (NCT04175600)
- Testing
- Selexipag, Standard of Care (SOC): Endothelin receptor antagonist, SOC: Phosphodiesterase type 5 (PDE-5) inhibitor
- Where
- 116 sites in United States, Australia and 30 more
- Volunteers
- 138 people
- Sponsor
- Actelion
Cystic Fibrosis
A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis
This study will evaluate the efficacy of tezacaftor in combination with ivacaftor (TEZ/IVA) in participants with cystic fibrosis (CF) aged 6 through 11 years, who are homozygous for the F508del mutation (F/F) or heterozygous for…
- Trial name
- NCT03559062
- Testing
- TEZ/IVA, IVA
- Where
- 27 sites in Australia, Belgium and 7 more
- Volunteers
- 67 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
COVID-19
Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Children and Adolescents
This study is a randomized, double-blinded, placebo-controlled, phase Ⅱb clinical trial of an inactivated SARS-CoV-2 vaccine (CoronaVac) manufactured by Sinovac Life Sciences Co.
- Trial name
- NCT04884685
- Testing
- SARS-CoV-2 Inactivated Vaccine
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Dup15Q Syndrome
A Phase II Study of Basmisanil in Children and Adolescents With Dup15q Syndrome
The primary goal of this Phase 2 clinical trial is to determine the effects of a selective negative allosteric modulator (NAM) of GABAA α5 receptor, Basmisanil (NTX-1511), on brain wave (EEG) characteristics in children and…
- Trial name
- NCT07846215
- Testing
- Basmisanil
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Newleos Therapeutics, Inc.
Inflammation
Efficacy of a Probiotic Strain on Level of Markers of Inflammation in an Elderly Population
To investigate the effectiveness of two doses of the probiotic strain Bif-038 on markers of low-grade inflammation in a elderly population
- Trial name
- NCT05529693
- Testing
- Experimental: Bif-038 arm, high dose, Experimental: Bif-038 arm, low dose
- Where
- Ireland
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Chr Hansen
Influenza
Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Different Suppliers
The purpose of this study is to assess the humoral immune response and safety of the parenteral formulation of the 2010/2011-season virosomal subunit influenza vaccine Inflexal V using two different HA antigen suppliers (AdImmune…
- Trial name
- NCT01412281
- Testing
- Virosomal influenza vaccine (AdImmune HA Antigen), Virosomal influenza vaccine (CSL HA Antigen)
- Where
- Switzerland
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
COVID-19
Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of COVID-19
This study is a randomized, double-blinded, and placebo controlled phase 1\&2 clinical trial of the SARS-CoV-2 inactivated vaccine manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT04551547
- Testing
- Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28, Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28
- Where
- China
- Volunteers
- 552 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
Moderate to Severe Acute Postoperative Pain
Use of Tapentadol Oral Solution for Pain After Surgery in Children From Newborn to Less Than 2 Years Old
This is a multicenter, open-label (all people involved know the identity of the intervention), single dose trial to evaluate the pharmacokinetic (PK) profile (how drugs are absorbed in the body, how are they distributed within…
- Trial name
- NCT02221674
- Testing
- Tapentadol
- Where
- 7 sites in United States, Poland and 1 more
- Volunteers
- 40 people
- Sponsor
- Grünenthal GmbH
Chronic Insomnia, Adults
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Bayesian Adaptive Randomization Design, Dose Response Study of the Efficacy of E2006 in Adults and Elderly Subjects With Chronic Insomnia
This is a multicenter, multiple dose, randomized, double-blind, placebo-controlled, parallel-group, Bayesian adaptive, dose response study in subjects with chronic insomnia.
- Conditions
- Chronic Insomnia, Adults, Elderly
- Trial name
- NCT01995838
- Testing
- E2006
- Where
- 29 sites in United States
- Volunteers
- 291 people
- Sponsor
- Eisai Inc.